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We aimed to estimate overall and cause-specific excess mortality of HIV-positive patients compared with the general population, and
to assess the effect of risk factors.
We included patients aged >19 years, recruited from January 1, 2004 to May 31, 2014 in Cohort of the Spanish Network on HIV/
AIDS Research. We used generalized linear models with Poisson error structure to model excess mortality rates.
In 10,340 patients, 368 deaths occurred. Excess mortality was 0.82 deaths per 100 person-years for all-cause mortality, 0.11 for
liver, 0.08 for non-AIDS-defining malignancies (NADMs), 0.08 for non-AIDS infections, and 0.02 for cardiovascular-related causes.
Lower CD4 count and higher HIV viral load, lower education, being male, and over 50 years were predictors of overall excess
mortality. Short-term (first year follow-up) overall excess hazard ratio (eHR) for subjects with AIDS at entry was 3.71 (95% confidence
interval [CI] 2.66, 5.19) and 1.37 (95% CI 0.87, 2.15) for hepatitis C virus (HCV)-coinfected; medium/long-term eHR for AIDS at entry
was 0.90 (95% CI 0.58, 1.39) and 3.83 (95% CI 2.37, 6.19) for HCV coinfection. Liver excess mortality was associated with low CD4
counts and HCV coinfection. Patients aged ≥50 years and HCV-coinfected showed higher NADM excess mortality, and HCV-
coinfected patients showed increased non-AIDS infections excess mortality.
Overall, liver, NADM, non-AIDS infections, and cardiovascular excesses of mortality associated with being HIV-positive were found,
and HCV coinfection and immunodeficiency played significant roles. Differential short and medium/long-term effects of AIDS at entry
and HCV coinfection were found for overall excess mortality.
Abbreviations: cART = combination antiretroviral therapy, CI = confidence interval, CoRIS = Cohort of the Spanish Network on
HIV/AIDS Research, eHR= excess hazard ratio, eMR= excess mortality rate, HBV= hepatitis B virus, HCV= hepatitis C virus, ICD =
International Classification of Diseases, IDUs = injection drug users, IQR = interquartile range, LD = late diagnosis, MSM =men who
have sex with men, NADM = non-AIDS-defining malignancies, py = person-years, VL = HIV viral load.
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remains as duration of HIV infection lengthens.[2–4] Hepatitis C
virus (HCV) and/or hepatitis B virus (HBV) coinfection and
tobacco use, together with long exposure to cART and long-
standing HIV replication, may further contribute to the
diversification of morbidity and mortality.[5–7] Studies from
several European countries have reported an important excess
mortality in HIV/HCV-coinfected patients.[8,9] However, it is
essential to determine the contribution of HCV coinfection to an
increased cause-specific mortality in HIV-positive patients.
Whereas most available data on excess mortality refer to all-
cause mortality, less data are available on the cause-specific
excess mortality associated with being HIV-positive. This is
important given that non-AIDS-definingmalignancies (NADMs),
cardiovascular disease, and liver-related deaths have become
more frequent as a consequence of more prolonged survival of an
increasingly HIV-positive population.[2,10]
Therefore, we aimed to evaluate the overall and cause-specific
excess mortality observed in HIV-positive subjects followed up in
the cohort of the Spanish Network on HIV/AIDS Research
(CoRIS) from 2004 to 2014, compared with the expected
mortality in the general population in Spain, and to identify
prognostic factors of excess mortality.2. Methods
2.1. Subjects
The CoRIS cohort or CoRIS is an open, multicentre, prospective
cohort of HIV-positive adults recruited while cART-naïve from
40 centers from 13 of the 17 Autonomous Communities of
Spain.[11] Ethics approval was obtained from all hospitals Ethics
Committees, and every patient provided written informed
consent to participate in the cohort.
For this analysis, we included patients older than 19 years
recruited from January 1, 2004 to May 31, 2014 (administrative
censoring date). Individuals were followed up from study entry to
death or last study contact, whichever arose first.2.2. Definition of variables
We considered the following variables: age at entry (20–49,≥50);
sex (male, female); HIV transmission category (injection drug
users [IDUs], men who have sex with men [MSM], heterosexual
contact, others); level of education (no education or compulsory
[which included primary and lower secondary], upper secondary,
university, others [no possible to classify according this system]);
geographical region of origin (Spain, Latin America, sub-Saharan
Africa, others); AIDS-defining condition at entry, CD4cells/mm3
count at entry (<200, 200–350, >350); HIV viral load (VL) at
entry copies/mL (<100000, ≥100000); HCV serological status at
entry (positive or negative antibodies); cART initiation in the first
6 months after cohort entry; vital status; cause and date of death.
Follow-up time was divided in 2 intervals: first year after the
inclusion in the cohort to account for short-term mortality, and
from the second year to the 10th year to account for medium/
long-term mortality.2.3. Classification of deaths in the general population and
in the cohort
Mortality rates in the general population, from 2004 to 2013,
were obtained from the National Institute of Statistics (www.ine.2
es), stratified by sex and age at 5-year intervals. A constant death
rate within each 5-year age interval was assumed.
Deaths were classified using revised CoDe in CoRIS and 10th
revision of the International Classification of Diseases (ICD-10) was
applied in the general population and grouped as: liver disease
(includingHCVandHBV-related liver cancers),NADM,non-AIDS
infections, and cardiovascular disease (see Table 1).[12] Revised
CoDe is a simplified version of CoDe coding system that has been
proposed by the Antiretroviral Therapy Cohort Collaboration
(ART-CC),[13] which has been previously applied to CoRIS.[12]2.4. Statistical analysis
Descriptive analysis of patients characteristics was performed
using frequency distributions for categorical variables and
median (interquartile range [IQR]) for continuous variables for
all and deceased patients.
Excess mortality rate associated with being HIV-positive is
defined as the difference between the death rate observed in the
cohort and the expected death rate in the general population. The
expected number of deaths was calculated by applying the
mortality rates of the general population to the person-years (py)
distribution of the HIV cohort matched by age, sex, and calendar
year at risk.We usedmultivariable generalized linearmodels with
Poisson error structure to estimate both the excess mortality rates
(eMRs) in HIV-positive patients compared with the general
population and the excess hazard ratio (eHR) for potential
prognostic factors. This latter estimation should be interpreted as
a common HR, but in terms of excess mortality.
A competing risk analog of the generalized linear model with
Poisson error structure was applied to estimate cause-specific
excess mortality in HIV-positive patients. We fitted separated
models for liver, NADM, non-AIDS infections, and cardiovas-
cular deaths; individuals who developed a competing event
before the event of interest were censored on the occurrence date
of the competing event.
In the multivariable models, we included all the prognostic
factors with P values <0.1 in the crude analysis, CD4 count at
entry, and follow-up interval (to assume piecewise constant
hazards in each interval). We checked the sensibility of these
assumption using 1-year intervals of follow-up (see Supplemen-
tary Fig. 1, http://links.lww.com/MD/B241). Further, to investi-
gate whether the effects of the prognostic factors on overall and
cause-specific excess mortality differed by follow-up interval,
interaction terms between follow-up intervals and prognostic
factors were tested. Due to the small number of events and to
avoid overfitting, we did not consider the variable “AIDS at
entry” for NADM, liver, and non-AIDS infections multivariable
models. We also checked that the number of observed deaths was
above the expected deaths in each subgroup.
“Multiple Imputation by Chained Equations”was used to deal
withmissing data.We developed amultiple imputation model for
each variable with missing values. Resulting models included the
other incomplete variables (education, HIV transmission, origin
region, CD4, VL, HCV, cause of death); the complete variables
(AIDS at entry, age, sex); the outcome (survival time, cause of
death); and 1 additional variable “receiving cART in the first 6
months after cohort entry). The results from the 12 imputed
datasets were combined using Rubin rules.[14] We assessed the
imputation procedure and its convergence. Finally, we performed
exhaustive sensitivity analysis comparing results obtained using
imputed values and using only complete cases or excluding
individuals with imputed outcomes.
Table 1





(%) py All causes eMR (95% CI)
Total 10,340 (100.0) 36984.18 368 (100.0) 0.82 (0.73, 0.93)
Sex
Male 8633 (83.5) 29,908.44 298 (81.0) 0.83 (0.73, 0.95)
Female 1707 (16.5) 7075.74 70 (19.0) 0.77 (0.57, 1.04)
Age at entry, y
20–49 9305 (90.0) 33,221.24 263 (71.5) 0.70 (0.61, 0.80)
≥50 1035 (10.0) 3762.94 105 (28.5) 2.27 (1.80, 2.86)
Median (IQR) 35 (29–43) 43 (39–51)
Education
No/compulsory 4035 (39.0) 14,796.26 235 (63.9) 1.40 (1.20, 1.62)
Upper secondary 2678 (25.9) 9810.65 62 (16.8) 0.47 (0.33, 0.68)
University 2803 (27.1) 9080.11 39 (10.7) 0.31 (0.21, 0.48)
Other 825 (8.0) 3297.16 32 (8.6) 0.80 (0.52, 1.22)
HIV transmission mode
IDU 1020 (9.9) 4253.34 115 (31.4) 2.59 (2.13, 3.14)
MSM 6082 (58.8) 19,719.48 94 (25.7) 0.36 (0.27, 0.46)
Heterosexual 3133 (30.3) 12,536.68 150 (40.7) 0.95 (0.78, 1.16)
Others 104 (1.0) 474.69 8 (2.3) 1.65 (0.80, 3.44)
Origin country
Spain 7164 (69.3) 26,814.86 305 (82.8) 0.94 (0.82, 1.08)
South-Saharan Africa 567 (5.5) 1902.41 15 (4.1) 0.69 (0.39, 1.23)
Latin America 1849 (17.9) 5999.15 32 (8.7) 0.46 (0.31, 0.69)
Others 761 (7.4) 2267.76 16 (4.4) 0.58 (0.32, 1.06)
CD4 at entry, cells/mm3
200 2576 (24.9) 10,051.65 226 (61.5) 2.05 (1.78, 2.37)
201–350 2057 (19.9) 7482.40 62 (16.9) 0.66 (0.48, 0.91)
>350 5707 (55.2) 19,450.13 79 (21.5) 0.28 (0.21, 0.38)
Median (IQR) 386 (200–586) 133 (40–311)
VL at entry, copies/mL
<20,000 3467 (33.5) 12,587.05 78 (21.1) 0.46 (0.34, 0.62)
20,000–100,000 3465 (33.5) 12,315.00 99 (27.0) 0.64 (0.50, 0.83)
>100,000 3407 (32.9) 12,082.13 191 (51.9) 1.39 (1.18, 1.65)
Median (IQR) 46,504 (11,800–151,000) 100,001 (31,622–350,000)
HCV at entry
Negative 8951 (86.6) 8950.50 222 (60.2) 0.53 (0.44, 0.63)
Positive 1390 (13.4) 1389.50 146 (39.8) 2.41 (2.02, 2.87)
AIDS at entry
No 9321 (90.1) 32,952.18 239 (64.9) 0.57 (0.48, 0.66)
Yes 1019 (9.9) 4032.00 129 (35.1) 2.98 (2.48, 3.58)
CI= confidence interval, HCV=hepatitis C virus, IDU= injection drug user, IQR= interquartile range, MSM=men who have sex with men, py=person-years, VL= viral load.
∗
Results are based on rounded mean values of the 12 imputed datasets; results may not always count up exactly to the total value.
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3. Results
3.1. Characteristics of the participants
The total number of patients older than 19 years included in
CoRIS from January 1, 2004 to May 31, 2014 was 10,340. The
median follow-up was 3.20 years (IQR 1.01, 5.66), and during
36,984.18 py of follow-up, 368 deaths were observed. The
distribution of causes of death in CoRIS and the general
population is presented in Supplementary Table 1 (http://links.
lww.com/MD/B241).
We found missing data on level of education (1349, 13.1%),
HIV transmission category (242, 2.3%), country of origin (218,
2.1%), CD4 count (775, 7.5%), VL (811, 7.8%), HCV
coinfection (1081, 10.5%), and cause of death (47, 12.8%
among death subjects). All missing values were imputed.3
After imputation of missing values, 83.5% were men,
39.0% had compulsory or no education, 9.9% were IDUs,
58.8% were MSM, and 30.3% were heterosexuals. Spain was
the country of origin of 69.3% of the patients, andmedian age at
cohort entry was 35 (IQR 29–42) years. Median CD4 count was
386cell/mm3 (IQR 200–586), median HIV VL was 46,504
copies/mL (IQR 11,800–151,000) and 1019 (9.9%) patients
with AIDS at entry. Overall, 13.4% had a positive HCV test
result at entry (Table 1).3.2. Overall excess mortality
The overall eMR observed in the cohort was 0.82 deaths per 100
py of follow-up (95% CI 0.73, 0.93), that is, the death rate was
0.82 deaths per 100 py higher in CoRIS than in the Spanish
population of the same age and sex for all causes of death. Overall
eMRs by potential prognostic factors are shown in Table 1. The
overall eMRwas 1.91 per 100 py (95%CI 1.63, 2.24) during the
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(95% CI 0.41, 0.60) during the rest of the follow-up.
In the multivariable model (Fig. 1), CD4 count and age at
cohort enrolment were strong predictors for excess mortality
adjusted for background mortality and all other risk predictors.
Excess mortality was higher in those with VL at entry >100,000
compared with those with VL<20,000 (eHR 1.48, 95%CI 1.02,
2.13). Excess mortality was 0.55 (95%CI 0.38, 0.81) times lower
in those with upper secondary and 0.52 (95% CI 0.33, 0.82) in
those with university education than in the group of no or
compulsory. Excess mortality was lower amongMSM compared
with IDUs (P=0.007). There was borderline evidence that
women had lower risk of excess mortality than men (eHR 0.75,
95% CI 0.54, 1.04). The short and medium/long-term effects of
having AIDS (P<0.001) and being HCV-positive (P<0.001) at
study entry on the excess mortality were significantly different;
having AIDS at entry was a strong predictor of short-term excess
mortality (eHR 3.65, 95% CI 2.62, 5.09), whereas this effect
disappeared (eHR 0.89, 95% CI 0.57, 1.39) during the rest of
follow-up. On the contrary, being HCV-positive at study entry
predicted higher long-term excess mortality (eHR 3.75, 95% CI
2.33, 6.06), whereas there was no evidence of a statistically
significant effect during the first year of follow-up (eHR 1.40,
95% CI 0.88, 2.24).
3.3. Cause-specific excess mortality
Non-AIDS-defining malignancies, liver, non-AIDS infections,
and cardiovascular deaths distribution and eMRs by potential
prognostic factors are shown in Table 2.Figure 1. Adjusted excess hazard ratio (eHR) for the associations between potenti
multivariable generalized linear model with Poisson error structure. P value derive
4
The eMR observed from 2004 to 2014 in CoRIS was 0.08
deaths (95% CI 0.05, 0.14) for NADM, 0.10 deaths (95% CI
0.07, 0.14) for liver, 0.08 deaths (95% CI 0.05, 0.11) for non-
AIDS infections, and 0.02 deaths (95%CI 0.00, 0.05) per 100 py
of follow-up for cardiovascular causes.
There was strong evidence that age and HCV coinfection at
entry were independently associated with a higher NADM
excess mortality. Patients aged 50 years old, or older at entry,
had 5.15 times higher risk (95% CI 2.33, 11.39) compared
with those aged below 50 years at entry, and the adjusted eHR
for those HCV-coinfected subjects was 3.85 (95% CI 1.45,
10.18) (Fig. 2).
A CD4 count at entry greater than 350cells/mm3 was
associated with a 74% reduction of the liver excess mortality
compared with CD4 counts lower than 200cells/mm3 (eHR 0.26,
95% CI 0.09, 0.71). HCV-coinfected subjects had 9.69 times
(95% CI 2.71, 34.60) higher risk of liver excess mortality than
HCV-negative ones. Besides, there was strong evidence that long-
term adjusted eHR was lower compared with short-term eHR
(eHR 0.37, 95% CI 0.19, 0.73).
Having a positive HCV test at entry was also associated with
higher non-AIDS infection-related excess mortality (eHR 5.27,
95% CI 1.66, 16.74), and there was strong evidence that long-
term adjusted eHR was lower compared with short-term eHR
(eHR 0.35, 95% CI 0.16, 0.78).
No significant predictor for the crude cardiovascular excess
mortality was found, hence multivariable generalized linear
model was not performed.
We failed to find any evidence that the effect of prognostic
factors on cause-specific excess mortality had changed over time,al risk factors and overall excess mortality rate. eHR and P values derived from a
d from Wald test. LA=Latin America, SSA=sub-Saharan Africa.
[18]
Table 2
Non-AIDS-definingmalignancies, liver, non-AIDS infections, cardiovascular-related deaths distribution and excessmortality rates (eMRs)
per 100 person-years of follow-up.
Non-AIDS-defining malignancies Liver Non-AIDS infections Cardiovascular
N
∗
eMR (95% CI) N
∗
eMR (95% CI) N
∗
eMR (95% CI) N
∗
eMR (95% CI)
Total 62 0.08 (0.05, 0.14) 40 0.10 (0.07, 0.14) 30 0.08 (0.05, 0.11) 11 0.02 (<0.01, 0.05)
Sex
Male 50 0.07 (0.04, 0.14) 29 0.10 (0.06, 0.14) 23 0.07 (0.05, 0.11) 10 0.02 (<0.01, 0.06)
Female 12 0.11 (0.05, 0.27) 10 0.13 (0.06, 0.27) 7 0.09 (0.04, 0.21) 2 <0.01 (NA)
Age at entry, y
20–49 34 0.06 (0.03, 0.11) 32 0.09 (0.06, 0.14) 23 0.07 (0.04, 0.11) 8 0.01 (<0.01, 0.06)
≥50 28 0.50 (0.28, 0.87) 7 0.17 (0.08, 0.39) 7 0.15 (0.06, 0.39) 3 0.04 (<0.01, 0.50)
Education†
No/compulsory 30 0.09 (0.04, 0.20) 28 0.18 (0.12, 0.27) 24 0.09 (0.06, 0.15)2 8 0.02 (0.01, 0.07)2
Upper secondary 18 0.10 (0.04, 0.22) 5 0.04 (0.01, 0.14) 1 1
University 8 0.02 (<0.01, 0.29) 4 0.03 (0.01, 0.13) 3 0.03 (0.01, 0.11) 0 <0.01 (<0.01, <0.01)
Others 6 0.16 (0.06, 0.41) 4 0.09 (0.03, 0.33) 2 0.06 (0.01, 0.27) 2 0.04 (0.00, 0.34)
HIV transmission mode
IDU 7 0.19 (0.07, 0.46) 28 0.64 (0.43, 0.96) 11 0.25 (0.13, 0.48) 1 0.01 (0.00, 5.41)
MSM 10 0.02 (0.01, 0.09) 2 0.01 (<0.01, 0.09) 5 0.02 (0.01, 0.06) 3 <0.01 (<0.01, 0.20)
Heterosexual 23 0.17 (0.10, 0.29) 10 0.07 (0.03, 0.15) 13 0.09 (0.05, 0.18) 6 0.02 (<0.01, 0.15)
Others 0 NA 0 NA 1 0.27 (0.04, 1.94) 1 0.30 (0.04, 2.43)
Origin
Spain 53 0.10 (0.06, 0.17) 37 0.13 (0.09, 0.18) 22 0.08 (0.05, 0.12) 8 0.01 (0.00, 0.21)
Others 8 0.04 (0.01, 0.15) 3 0.02 (0.01, 0.10) 8 0.07 (0.03, 0.15) 3 0.03 (0.01, 0.11)
CD4 at entry, cells/mm3
200 29 0.18 (0.10, 0.34) 23 0.09 (0.06, 0.14) 15 0.14 (0.08, 0.24) 6 0.03 (0.01, 0.15)
201–350 14 0.09 (0.03, 0.30) 10 0.12 (0.06, 0.26) 6 0.07 (0.03, 0.18) 4 0.04 (0.01, 0.20)
>350 18 0.03 (0.01, 0.11) 7 0.03 (0.01, 0.08) 10 0.05 (0.02, 0.09) 2 <0.01 (NA)
VL at entry, copies/mL
<20,000 15 0.05 (0.01, 0.19) 12 0.09 (0.05, 0.18) 9 0.07 (0.03, 0.15) 6 0.02 (<0.01, 0.13)
20,000–100,000 17 0.06 (0.02, 0.18) 14 0.10 (0.05, 0.20) 8 0.06 (0.02, 0.15) 3 0.01 (<0.01, 10.85)
>100,000 30 0.15 (0.08, 0.28) 13 0.10 (0.06, 0.19) 12 0.10 (0.05, 0.18) 3 0.02 (<0.01, 0.11)
HCV at entry
Negative 42 0.06 (0.03, 0.12) 7 0.02 (0.01, 0.05) 13 0.03 (0.02, 0.07) 7 0.01 (<0.01, 0.06)
Positive 20 0.29 (0.15, 0.57) 33 0.56 (0.39, 0.81) 16 0.28 (0.17, 0.48) 5 0.05 (0.01, 0.24)
AIDS at entry
No 46 0.06 (0.03, 0.12) 33 0.09 (0.06, 0.14) 23 0.06 (0.04, 0.10) 10 0.02 (<0.01, 0.05)
Yes 16 0.28 (0.14, 0.55) 7 0.15 (0.07, 0.35) 7 0.16 (0.07, 0.37) 1 0.01 (<0.01, 17.06)
Follow-up, y
1 17 0.10 (0.05, 0.24) 16 0.18 (0.11, 0.30) 13 0.14 (0.08, 0.25) 4 0.03 (0.01, 0.13)
2–10 45 0.07 (0.04, 0.14) 24 0.07 (0.05, 0.12) 17 0.06 (0.03, 0.10) 8 0.01 (<0.01, 0.27)
CI= confidence interval, HCV=hepatitis C virus, IDU= injection drug user, MSM=men who have sex with men, NA=not a number, VL= viral load.
∗
Results after imputation are based on rounded mean values of the 12 imputed datasets; results may not always count up exactly to the total value.
† Level of education was classified as “no/compulsory/upper secondary,” “university” and “others” for non-AIDS infections and cardiovascular excess mortality.
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numbers are small.4. Discussion
The HIV-positive subjects in Spain have experienced, from 2004
to 2014, an overall excess mortality, and also an excess mortality
for NADM, liver, non-AIDS infections, and cardiovascular
disease compared with the general population of the same age
and sex. These mortality excesses have happened largely at the
expense of higher rates in the first year after cohort inclusion, and
are attributable to late HIV presentation, which could be greatly
attenuated by scaling up HIV testing and early diagnoses.
The excess mortality in HIV-positive patients has been
reported both in Spain and elsewhere.[15–17] The higher excess
rates compared with CoRIS reported by Aldaz et al[16] can be
explained by their higher proportion of IDUs. The concerted
action on seroconversion to AIDS and death in Europe
(CASCADE) collaboration reported an excess mortality of 0.65
deaths per 100 py during 2004 to 2006. CASCADE collects
data from seroconverters, hence the discrepancies with our results
can be explained by different study populations. Not surprising-
ly, short-term mortality is less likely to happen in seroconverters
because of the better clinical and immunological conditions at
cohort entry; indeed CASCADE’s overall excess mortality rate is
similar to the 0.50 per 100 py found in CoRIS after excluding
short-term mortality. Subjects with AIDS at cohort enrolment—
subjects with late HIV presentation—had an increase of excess
mortality during the first year of follow-up. The implications of a
delayed HIV diagnosis have been previously documented.[19]
AIDS diagnosis has been related with poorer responses to
cART.[20]
Previous reports in CoRIS had also noticed the importance of
HCV/HIV coinfection on overall and cause-specific mortality in
the Cohorts of the Spanish AIDS Research Network.[15,21,22] Our
finding about the differential effect of HCV coinfection on short
and long-term excess mortality raises again the question about
the role of HCV coinfection in mortality associated with HIV
Figure 2. Adjusted cause-specific excess hazard ratio (eHR) for the associations between potential risk factors and cause-specific excess mortality rate. eHR
derived from a multivariable generalized linear model with Poisson error structure. LA=Latin America, SSA=sub-Saharan Africa.
Alejos et al. Medicine (2016) 95:36 Medicineinfection, even adjusting for background mortality. Excess
mortality captures both direct and indirect effects of HIV
infection on mortality. Long-term excess mortality in HCV-
coinfected patients may be explained by the direct impact of HCV
onHIV disease progression for which data are inconsistent. Some
reports have found no evidence that HCV infection accelerates
CD4 decline and AIDS progression, nor that it compromises CD4
count recovery after initiation of cART.[23,24] Other studies have
reported that HCV coinfection is associated with a higher risk of
progression to AIDS[25] and poorer CD4 recovery even after
several years from cART initiation.[26] Berenguer et al[27]
published that the eradication of HCV in HIV/HCV-coinfected
patients is associated with decreases in HIV progression and
lower risks of both liver and nonliver-related mortality. Long-
term overall excess mortality in HCV-positive patients can be
also explained by indirect mortality associated to higher exposure
to drugs, alcohol, and tobacco, compared with the general
population.[9]
Liver excess mortality associated with being HIV-positive can
be mediated by the direct impact HIV has on the natural history
of HCV.[28] Besides, the toxicity of long-term antiviral treatment
may contribute to liver damage and liver excess mortality.[29]
However, there is also indirect effect since hepatotoxic substances
such as alcohol and illegal drugs are abused by HIV-positive
subjects more often than the general population.[30]
We observed significantly higher NADM mortality among
HIV-positive patients compared with the general population,
which is consistent with previous reports.[31] NADM excess
mortality can be both directly and indirectly associated with HIV.
Some studies have suggested that immunosuppression might be
associatedwithmoderated excesses of NADM[32] andmore rapid
progression of some types of cancer.[33] Besides, clear associa-
tions between immunosuppression and NADMwith known viral
etiology have been reported.[33,34] NADM excess mortality can
be also attributable to the previously alleged elevated frequency
of cancer risk factors in HIV-positive patients such us smoking
and alcohol abuse,[30,35] and coinfection with oncogenic virus
such as hepatitis D virus, HCV, HBV, and human papilloma
virus.[36]
Hepatitis C virus coinfection and aging have been previously
reported as risk factors for excess NADM rates.[31,33] Patients6
older than 50 years have shown a poorer immunological response
to cART[37] which might also contribute to the higher NADM
excess mortality observed in older patients.
Competing explanations for lower mortality rates in migrant
populations fall into 2 broad categories. The first posits the self-
selection of healthier migrants driven by labor market conditions
in what is known as the “healthy immigrant effect.”[38] A second
hypothesis, known as “Salmon bias,” proposes that foreign-born
persons return to their country of origin when they become severe
ill.[39] Therefore, our analysis should have used general
population mortality rates matched by sex, age, and also region
of origin, but unfortunately, cause-specific mortality rates by
country of origin are not accessible in Spain.
There are some study limitations that merit discussion. As in
other studies, some covariates (e.g., adherence to cART, alcohol
and tobacco use, access/adherence to interferon/ribavirin, HCV-
RNA determination) were not collected and consequently their
impact on the results could not be analyzed. Another aspect that
could be argued is the convenience of using different coding
algorithms in the numerator and denominator of excess mortality
estimations. However, it has been shown that revised CoDe
classification is the best way to classify cause of death in HIV-
positive cohort studies; it has been shown that applying ICD-10
systemwould underestimate liver mortality associated with being
HIV-positive.[12] Selection bias could have been introduced by
the use of the general population as a proxy for background
population as this population contains also HIV-related deaths.
Nevertheless, as HIV-related mortality represents a small
proportion of all-cause mortality in the general population of
Spain, we consider correct it to use the general population
mortality rates to calculate the mortality rates in a non-HIV-
infected population. Misclassification of missing data due to
imputation could also be discussed. However, sensitivity analysis
restricted to complete cases did not reveal changes in the direction
of the association between excess mortality and risk factors.
Finally, the low number of deaths, when aiming to look at cause-
specific mortality, may have introduced random error in some of
our estimates and comparisons.
To conclude, our results have shown overall, NADM, liver,
infection, and cardiovascular excess mortality associated with
being HIV-positive despite improvements in HIV disease
Alejos et al. Medicine (2016) 95:36 www.md-journal.commanagement. As far as we know, no previous analysis has
demonstrated in this very clear way the role of having an AIDS
diagnosis at entry in early excess mortality and HCV coinfection
in long-term excess mortality. Our results have clear implications
for health policy in that promoting earlier HIV diagnosis and
linkage to care will likely decrease the excess of mortality detected
in the first year. It is to be expected that the scale-up of the
treatment with new direct acting antivirals for HCV will impact
long-term mortality too. Finally, increased efforts promoting
healthier lifestyles regarding diet, smoking, and exercise are
urgently needed in the current context to aim for the healthy
aging of the persons living with HIV.Acknowledgments
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